Biotech News

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Prime Medicine (PRME)Prime MedicineFinancing

CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 41,071,428 shares of its

Related news

Prime Medicine

Prime Editing Prime Medicine develops genetic medicines using Prime Editing, a technology designed to make precise DNA changes without requiring double-strand breaks. Its programs target diseases that may be addressed by correcting pathogenic variants in vivo or ex vivo. PM577 PM577 is an in vivo Prime Editing candidate designed to...

Recent company news

Stock data

Close
3.84 USD
Market cap
579.78M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States